The short version of REV-ERB agonist fits in a sentence. The long version — which is the one that helps — is below.
This page was last updated on 2026-02-14 and is reviewed periodically as new material appears.
Research interest in SR9009 grew from studies showing improved running endurance in mice after short treatment periods. Those experiments linked the compound to increased mitochondrial content and fatty acid oxidation in muscle, but the findings come from animal models and specific dosing schedules. Independent replication has been limited, and the pathways connecting REV-ERB activation to exercise performance are still being mapped. Whether similar responses occur in humans is an open question.
SR9009 is often grouped with compounds studied for circadian and metabolic regulation rather than with classical anabolic steroids. Its interactions with nuclear receptors differ from those of androgen receptor ligands, and its proposed mechanisms involve transcriptional control rather than direct hormone signaling. Some sources classify it as a metabolic modulator because of observed effects on energy utilization. The distinction matters for regulation and for interpreting research results across different compound classes.
SR9009 is frequently discussed in fitness and research-chemical contexts, yet it has no approved medical indication. Regulatory agencies have not authorized it for human use, and it is not a standard prescription drug. Some sports organizations list it as a prohibited substance because of its potential performance-enhancing properties. Published human data are sparse, so claims about its effects in people often rely on animal models or anecdotal reports. Quality and identity of online materials can vary widely.
SR9009 is a synthetic small molecule studied as a REV-ERB agonist. REV-ERBα and REV-ERBβ are nuclear receptors that help regulate circadian rhythms and metabolic gene expression. The compound was identified in academic screening efforts to find synthetic ligands for these receptors. In cell and animal studies, SR9009 alters transcription of genes involved in lipid and glucose metabolism, and it can shift circadian behavior. It is not an approved therapeutic agent.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C20H24ClN3O4S | Reported for the free base |
| Molecular weight | 437.9 g/mol | Calculated from the formula |
| Primary target | REV-ERBα and REV-ERBβ | Nuclear receptors involved in circadian regulation |
| Solubility | Soluble in DMSO and ethanol | Poorly soluble in water |
| Typical storage | -20 °C, desiccated | Protect from light and moisture |
At the molecular level, SR9009 binds the ligand-binding domain of REV-ERB and strengthens recruitment of corepressor proteins such as NCoR and HDAC3. This increases repression of target genes, including Bmal1 and other clock-controlled and metabolic genes. In rodent studies, such changes have been linked to altered lipid handling, glucose metabolism, and energy expenditure. The precise chain of events between receptor binding and whole-body effects remains an active area of research. Findings in animals do not automatically translate to humans.
Laboratory studies often administer SR9009 by injection because oral absorption appears poor in rodents. Reported pharmacokinetic properties include rapid metabolism and low systemic exposure after oral dosing. Human pharmacokinetic data are sparse, so absorption, distribution, metabolism, and excretion in people are not well defined. Some research explores related REV-ERB compounds with improved drug-like properties. Regulatory approval for any REV-ERB agonist as a human medicine has not been granted to date.
Pharmacokinetic data for SR9009 are limited in published literature. Some reports indicate low oral bioavailability and rapid clearance in animals, which complicates interpretation of exposure and effect. Researchers often use injected routes in preclinical work to achieve measurable systemic levels. Analytical studies rely on mass spectrometry to detect the parent compound and its metabolites. Questions about tissue distribution, active metabolites, and long-term consequences remain open. Species differences in metabolism can affect observed half-life and target engagement.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. These receptors help regulate circadian rhythms and metabolic gene expression. In laboratory experiments, SR9009 binds these receptors and alters transcription of genes involved in lipid handling, glucose metabolism, and mitochondrial function. It is not a naturally occurring compound and has no approved therapeutic use. Research interest stems from its ability to modify energy metabolism in cells and animal models.
Regulatory and sporting contexts treat SR9009 as a prohibited substance in many elite competitions. Its presence on banned lists reflects concerns about performance enhancement and unknown long-term safety. Analytical chemists have developed methods to detect the parent compound and its metabolites in urine and blood. Literature discussions distinguish between in vitro potency, animal pharmacology, and anecdotal human reports. The latter are difficult to verify because products sold online may lack purity or contain different compounds.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. These receptors help regulate circadian rhythms, lipid metabolism, and inflammatory gene expression. In cell and animal experiments, SR9009 alters transcription of clock-controlled genes and metabolic pathways. The compound is not a hormone and does not resemble classical steroid structures. Its activity depends on binding to the ligand-binding domain of REV-ERB, where it can modify corepressor recruitment.
=== RMI Staffing === Remote Medical International medical providers are available for onsite deployments operating in remote areas worldwide. Medical providers include experienced EMTs, paramedics, physician assistants, nurses, and doctors who respond to routine and emergent medical incidents. RMI medics are most commonly deployed on offshore seismic research vessels and land-based mineral exploration and production sites.
Miso: A fermented soybean paste that is a cornerstone of Japanese cuisine. Its production involves combining koji (usually rice-based) with cooked soybeans and salt, followed by fermentation for weeks or even years. Enzymes in the koji break down complex proteins and carbohydrates in the soybeans, creating miso's rich and nuanced flavor. The fermentation time, type of koji, and additional ingredients all contribute to a wide variety of miso types, from sweet white miso to robust red miso. Miso adds depth and complexity to dishes such as soups, stews, marinades, and sauces. Sake: In sake production, koji converts rice starch into fermentable sugars. Unlike beer brewing, where saccharification and fermentation occur sequentially, sake brewing integrates these stages in a parallel fermentation environment. This dynamic interplay contributes to sake's unique flavor profile. Koji not only facilitates starch conversion but also develops nuanced aromas and flavors in the final product. Soy Sauce: A fermented condiment derived from soybeans and wheat, with koji initiating enzymatic breakdown. Koji is cultivated on roasted wheat and soybeans and then mixed with salt water to create a brine called moromi, which ferments for months. Koji enzymes break down proteins and starches, contributing to soy sauce's umami flavor. After fermentation, the moromi is pressed, pasteurized, filtered, and bottled.
Plasma glucose level, not point-of-care measurement Insulin level C-peptide level Proinsulin level Beta-hydroxybutyrate level Oral hypoglycemic agent screen Response of blood glucose level to glucagon Insulin antibodies If necessary, a diagnostic hypoglycemic episode can be produced in an inpatient or outpatient setting. This is called a diagnostic fast, in which a patient undergoes an observed fast to cause a hypoglycemic episode, allowing for appropriate blood work to be drawn. In some, the hypoglycemic episode may be reproduced simply after a missed meal, whereas in others a fast may last up to 72 hours. In those with a suspected insulinoma, imaging is the most reliable diagnostic technique, including ultrasound, computed tomography (CT) imaging, and magnetic resonance imaging (MRI).
=== Etymology === Lactobacillic acid and Lactobacillussäure are translations of the English term 'lactobacillic acid', which scientists proposed when this fatty acid was discovered (1950) in a Lactobacillus species. In the German-language literature, the term lactobacillic acid is used more frequently than lactobacillus acid. As early as 1938, another group of researchers discovered an unusual fatty acid from the bacterium Agrobacterium tumefaciens (at that time called Bacterium tumefaciens or Phytomonas tumefaciens) was isolated and after the generic name as phytomonic acid. According to the knowledge of scientists at the time, this saturated fatty acid had the molecular formula C20H40O2. The proposed structure was a branched-chain fatty acid with a methyl group as a branch, methylnonadecanoic acid. However, K. Homann et al. were able to show in 1955 that this compound isolated from P. tumefaciens was in fact lactobacillic acid. According to them, the substance originally investigated had been contaminated.
By the mid-2020s, Zipline had become an example of a Silicon Valley startup whose most visible commercial activity occurred abroad rather than domestically, with most of its business based on government contracts for transporting medical supplies to remote or hard-to-reach areas in multiple African countries. In April 2024, Zipline completed its millionth commercial delivery, having flown more than 70 million autonomous commercial miles. In January 2026, Zipline completed its two millionth commercial delivery, with over 120 million autonomous miles flown.
Sources: en.wikipedia.org
Most of the high or low affinity bindings require chelation or competitive titration. This method is done by loading pre-bound complex solution in the sample cell and chelating one of the components out with a reagent of higher observed binding affinity within the desirable c-window. In order to ensure optimum instrument stability, the ITC instrument should be powered on at least one day before use. Samples should ideally be pre-equilibrated to approximately 2 °C below the target experimental temperature to reduce stabilization time after loading, although starting at the exact experimental temperature is also an option. For instrument cleaning, sample cell should be rinsed with the experimental buffer and dried under vacuum, and any remaining rinsed solution should be discarded manually with a syringe. Then, the sample cell is filled with the experimental solution and the reference cell with either high-purity water or the same buffer. To prevent air contamination, gas-tight Hamilton syringes are used, ensuring the needle is positioned near the bottom of the sample cell before dispensing the liquid slowly. Experimental parameters such as the number of injections, initial injection volume, subsequent injection volumes, temperature, reference power, stirring speed, spacing, initial delay, and filter period should be adjusted according to the specific study. If the experiment is to be repeated, the syringe should be emptied, with the solution either discarded or saved for further analysis.
Feathers are a feature characteristic of birds (though also present in some dinosaurs not currently considered to be true birds). They facilitate flight, provide insulation that aids in thermoregulation, and are used in display, camouflage, and signalling. There are several types of feathers, each serving its own set of purposes. Feathers are epidermal growths attached to the skin and arise only in specific tracts of skin called pterylae. The distribution pattern of these feather tracts (pterylosis) is used in taxonomy and systematics. The arrangement and appearance of feathers on the body, called plumage, may vary within species by age, social status, and sex. Plumage is regularly moulted; the standard plumage of a bird that has moulted after breeding is known as the "non-breeding" plumage, or—in the Humphrey–Parkes terminology—"basic" plumage; breeding plumages or variations of the basic plumage are known under the Humphrey–Parkes system as "alternate" plumages. Moulting is annual in most species, although some may have two moults a year, and large birds of prey may moult only once every few years. Moulting patterns vary across species. In passerines, flight feathers are replaced one at a time with the innermost primary being the first. When the fifth of sixth primary is replaced, the outermost tertiaries begin to drop. After the innermost tertiaries are moulted, the secondaries starting from the innermost begin to drop and this proceeds to the outer feathers (centrifugal moult). The greater primary coverts are moulted in synchrony with the primary that they overlap.
Governor Mike Parson appointed Schmitt as Missouri Attorney General to succeed Josh Hawley, who was elected to the U.S. Senate in 2018. Schmitt took office in January 2019. In 2020, he was elected to a full term. Schmitt resigned as attorney general in 2023 after his election to the U.S. Senate in 2022.
=== Pharmacokinetics === The pharmacokinetics of honokiol have been explored in rats and mice; however, further research must be done in humans. Intravenous delivery of 5–10 mg/kg in rodent models has shown a plasma half-life of around 40–60 minutes while intraperitoneal injections of 250 mg/kg had a plasma half-life around 4–6 hours with maximum plasma concentration occurring between 20 and 30 minutes.
Sources: en.wikipedia.org
It is a synthetic REV-ERB agonist used mainly in preclinical research. It is not an approved medicine for human use.
It binds to REV-ERBα and REV-ERBβ, nuclear receptors involved in circadian and metabolic gene regulation. This can alter transcription of genes related to lipid and glucose metabolism in experimental models.
No controlled human trials have established that effect. Endurance findings come primarily from rodent studies, and human responses remain unknown.
SR9009 is a synthetic compound investigated as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. It is used in preclinical research on circadian rhythm and metabolism. It is not an approved drug.